Trending Topic
On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]
It was fantastic to meet up with Jost Jonas (Ruprecht-Karls University) to discuss the Keynote Lecture ‘Myopia: Epidemiology, Histology & Clinics’ he presented at this year’s meeting.
Support: No funding was received in the production of this video.
Disclosures: Jost Jonas has nothing to disclose in relation to this video.
Trending Topic
The RESTORE trial (NCT04945772) is a phase 2b randomized, sham-controlled, multi-centre, multi-dose, double-masked clinical trial evaluating the efficacy and safety of MCO-010 optogenetic therapy in adults with retinitis pigmentosa. MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical […]
Retinitis pigmentosa is an inherited retinal dystrophy (IRD) caused by the loss of photoreceptors and characterized by retinal pigment deposits visible on fundus examination. Retinitis pigmentosa is the most common group of IRD. It was a pleasure to speak with ...
It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about new and emerging neovascular age-related macular degeneration treatments, including the new anti-vascular endothelial growth factor which appear to lead to better outcomes ...
It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about the problems with the clinical utility of vascular endothelial growth factor inhibitors and the issues around durability and ensuring good outcomes in ...
It was a pleasure to talk to Roxane Hillier (Newcastle Eye Centre, Newcastle, UK) on her EURETINA course on rhegmatogenous retinal detachment repair. In this interview, she discussed the treatment options for rhegmatogenous retinal detachment. The instructional course entitled “Mechanisms ...
In this touchOPHTHALMOLOGY interview, Roxane Hillier (Newcastle Eye Centre, Newcastle, UK) discussed techniques involved in retinal reattachment and shared the highlights from her EURETINA course on rhegmatogenous retinal detachment repair. The instructional course entitled “Mechanisms of Action in Rhegmatogenous Retinal ...
In this touchOPHTHALMOLOGY interview, Prof. Francesco Bandello (Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele, Milan, Italy) talks us through the advantages of optical coherence tomography angiography (OCTA) over conventional dye angiography in age-related macular degeneration (AMD) and a ...
In this touchOPHTHALMOLOGY interview, Prof. Francesco Bandello (Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele, Milan, Italy) discussed the findings of a study investigating the relationship between optical coherence tomography angiography and fluorescein angiography/indocyanine green angiography in AMD ...
Prof. Bart Leroy (Ghent University, Ghent, Belgium) joined touchOPHTHALMOLOGY in an interview to speak about RNA interference therapy and its advantages in treating inherited retinal diseases caused by CEP290 mutations. ‘RNA Interference Therapy for CEP290-IRD’ was presented at EURETINA 2022, 1–4 ...
The Archway study (NCT03677934) was a phase 3, randomized, active treatment–controlled trial for the treatment of nAMD, conducted at 77 study locations in the United States. We caught up with Prof. Usha Chakravarthy (Queen's University of Belfast, Belfast, Northern Ireland) to ...
In this interview on her EURETINA presentation, Prof. Kyoko Ohno-Matsui (Tokyo Medical and Dental University, Tokyo, Japan) discussed choroidal venous structures and how they change in myopic eyes. ‘Anomalies of choroidal venous structures in high myopia’ was presented at EURETINA 2022, 1–4 ...
Type 1 neovascularization can be a secondary feature of central serous chorioretinopathy. In this touchOPHTHALMOLOGY interview, Dr Dinah Zur (Center for Retinal Degenerations, Ophthalmology Division, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel) talks us through the implications of improper diagnosis of this ...
Universal mask use was shown to be effective at reducing incidence of endophthalmitis, according to results of a study presented at Hawaiian Eye 2022. We caught up with Dr Sunir Garg (Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Or use a .
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
